
## ERK activation globally downregulates miRNAs through

## phosphorylating exportin-5

Hui-Lung Sun<sup>1,2</sup>, Ri Cui<sup>1</sup>, Yong Peng<sup>3</sup>, Kun-yu Teng<sup>4</sup>, Yung-Hsuan Hsiao<sup>5</sup>, Kotaro Nakanishi<sup>6</sup>, Matteo Fassan<sup>1,7</sup>, Jih-Hwa Guh<sup>8</sup>, Kalpana Ghoshal<sup>4</sup>, Mien-Chie Hung<sup>9</sup>, Che-Ming Teng<sup>2</sup>, Carlo M. Croce<sup>1</sup>

Category: Molecular, metabolic and Structural biology

MicroRNAs (miRNA) are mostly downregulated in cancer. Systemic evaluation of miRNA has revealed that many pre-miRNA were retained in the nucleus of cancer cells. However, the mechanism underlying this phenomena and the precise consequence for tumorigenesis remains obscure. Here we showed that ERK suppresses pre-miRNA export from nucleus through phosphorylation of exportin-5 (XPO5) at T345/S416/S497. After phosphorylation by ERK, conformation of XPO5 is changed by prolyl isomerase Pin1, resulting in reduction of pre-miRNA loading. ERK also phosphorylates NUP153 to further inhibit pre-miRNA-XPO5 complex export. Globally miRNA downregulation was observed in liver cancer when XPO5 was phosphorylated, including the highly expressed miRNA, miR-122. Depletion of miR-122 increase SEPT9 expression to scaffold MAP4 and MARK4. Phosphorylated MAP4 detach from tubulin to increase microtubule dynamics, thereby inducing taxol resistance and tumorigenesis. Analysis of clinical specimens further showed that XPO5 phosphorylation is associated with poor prognosis for liver cancer patients. Our study reveals a novel function of ERK in miRNA biogenesis and suggests that modulation of miRNA export has potential clinical implications.



<sup>&</sup>lt;sup>1</sup>Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University

<sup>&</sup>lt;sup>2</sup>Pharmacological Institute, College of Medicine, National Taiwan University

<sup>&</sup>lt;sup>3</sup>State key laboratory of Biotherapy and Collaborative Innovation Center, Sichuan University

<sup>&</sup>lt;sup>4</sup>Department of Pathology, Ohio State University

<sup>&</sup>lt;sup>5</sup>Department of Human Nutrition, Ohio State University

<sup>&</sup>lt;sup>6</sup>Department of Chemistry and Biochemistry, Ohio State University

<sup>&</sup>lt;sup>7</sup>ARC-NET Research Centre, University and Hospital Trust of Verona

<sup>&</sup>lt;sup>8</sup>School of Pharmacy, National Taiwan University

<sup>&</sup>lt;sup>9</sup>Department of Molecular and Cellular Oncology, MD Anderson Cancer Center